A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery

Inclusion Criteria:

• Males and females ≥ 18 years of age
• Willing to sign the informed consent and deemed capable of following the studyprotocol
• Subjects must have a diagnosis of upper extremity edema and have or will undergolymphatic surgery with Dr. Nguyen
• Subjects must have a difference in volume greater than 3% between the limbs.

Exclusion Criteria:

• Individuals with a history or presence of a systemic disorder or condition that couldplace the patient at increased risk from sequential compression therapy
• Inability or unwillingness to participate in all aspects of study protocol and/orinability to provide informed consent
• Patients with exam results that would prevent safe and effective use of the studydevice (cellulitis, open-wounds, healing-wounds, etc.)
• Diagnosis of active or recurrent cancer, or less than 3 months at the time of initialevaluation from the completion of chemotherapy, radiation therapy or primary surgeryfor the treatment of cancer
• Patients must not have any diagnosed cognitive or physical impairment that wouldinterfere with use of the device
• Diagnosis of lipedema
• Diagnosis of acute infection. The source of the infection must be treated for 2 weeksprior to admittance into the study
• Diagnosis of acute thrombophlebitis (in last 2 months)
• Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months
• Diagnosis of pulmonary edema
• Diagnosis of congestive heart failure (uncontrolled)
• Diagnosis of chronic kidney disease
• Diagnosis of epilepsy
• Patients with poorly controlled asthma
• Women who are pregnant, planning a pregnancy or nursing at study entry
• Participation in any clinical trial of an investigational substance or device duringthe past 30 days
• Bilateral limb edema